jain.com

At-the-market share program

Company: CoreWeave

Subject kind
financing
Statement date
2026-09-17
Promised amount
35.0 units
Current status
verified

The claim, verbatim

CoreWeave outlined an equity distribution agreement to sell up to 35 million Class A shares through an at-the-market program.

Source (primary)

Why CoreWeave Is Tumbling Hard While the Market Is Soaring - 24/7 Wall St. (-, news_article)
View cached copy (2026-09-20)Live source ↗

Quote: “equity distribution agreement to sell up to 35 million Class A shares through an at-the-market program”

How we checked this

Checked on November 11, 2026. The cited source supports every part of this claim.

The article states that, alongside its convertible notes offering, CoreWeave outlined an equity distribution agreement to sell up to 35 million Class A shares through an at-the-market program. Every part of the claim is established by this document.

Confirmed in the source:

What we did: Read our cached copy of the publisher (https://247wallst.com/investing/2026/09/17/why-coreweave-is-tumbling-hard-while-the-market-is-soaring/) in full (11,301 characters, retrieved September 20, 2026) and checked each assertion in the claim against it.

Additional evidence

confirms Why CoreWeave Is Tumbling Hard While the Market Is Soaring - 24/7 Wall St.

Quote: “equity distribution agreement to sell up to 35 million Class A shares through an at-the-market program”

View cached copy (2026-09-20)Live source ↗

confirms What Is Driving The Fall In CoreWeave Stock? - Yahoo Finance

Quote: “on September 17 it set up a program to sell additional shares into the market”

View cached copy (2026-11-10)Live source ↗Archive.org ↗

Record of changes

September 20, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
November 10, 2026 — verified
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.